

## Geralyn M. Lambert-Messerlian, Ph.D.

### PEER-REVIEWED PUBLICATIONS

1. Villars TA, Erskine MS, Lambert GM, Jacobson D, Weaver CE and Baum MJ. Endocrine correlates of mating induced reductions in estrous behavior in an induced ovulator, the ferret. *Hormones and Behavior* 24: 198-214, 1990.
2. Lambert GM, Erskine MS and Baum MJ. Effect of naloxone on the pulsatile secretion of luteinizing hormone in gonadectomized male and female ferrets. *Journal of Neuroendocrinology* 2(5): 701-705, 1990.
3. Lambert GM and Baum MJ. Reciprocal relationships between pulsatile androgen secretion and the expression of mating behavior in adult male ferrets. *Hormones and Behavior* 25: 382-393, 1991.
4. Lambert GM, Rubin BS and Baum MJ. Sexual dimorphism in the effects of mating on *in vitro* release of LHRH from the ferret medio-basal hypothalamus. *Physiology and Behavior* 52: 809-813, 1992.
5. Lambert GM, Rubin BS and Baum MJ. Sex difference in the effect of mating on *c-fos* expression in luteinizing hormone releasing hormone neurons of the ferret forebrain. *Endocrinology* 131(3): 1473-1480, 1992.
6. Lambert-Messerlian GM, Isaacson KI, Crowley WF Jr, Sluss PM and Schneyer AL. Human follicular fluid contains pro- and C-terminal immunoreactive alpha-inhibin precursor proteins. *Journal of Clinical Endocrinology and Metabolism* 78(2): 433-439, 1994.
- \*7. Lambert-Messerlian GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WF Jr and Schneyer AL. Relatively low levels of dimeric inhibin in men and women with PCOS using a specific twosite ELISA. *Journal of Clinical Endocrinology and Metabolism*, 79(1): 45-50, 1994.
8. Lambert-Messerlian GM, Crowley WF Jr and Schneyer AL. Extragonadal alpha inhibin precursor proteins circulate in human male serum. *Journal of Clinical Endocrinology and Metabolism*, 80(10): 3043-3049, 1995.
9. Good TEM, Weber PSD, Ireland JLH, Pulsaki J, Padmanabhan V, Schneyer AL, Lambert-Messerlian G, Ghosh BR, Miller WL, Groome N and Ireland JJ. Isolation of nine different biologically and immunologically active molecular variants of bovine follicular inhibins. *Biology of Reproduction*, 53: 1478-1488 1995.
10. Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P and Crowley WF Jr. Follistatinactivin complexes in human serum and follicular fluid differ immunologically and biochemically. *Endocrinology*, 137: 240-247, 1996.
11. Seifer DB, Lambert-Messerlian GM, Canick JA, Frishman GN and Schneyer AL. Serum inhibin levels are lower in ectopic than intrauterine spontaneously conceived pregnancies. *Fertility and Sterility*, 65(3): 667-669, 1996.
12. Seifer DB, Gardiner A, Lambert-Messerlian G and Schneyer A. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. *Journal of Clinical Endocrinology and Metabolism*, 81(2): 736-739, 1996.
- \*13. Lambert-Messerlian GM, Palomaki GE, Schneyer AL and Canick JA. Second trimester levels of maternal serum inhibin A, total inhibin, " inhibin precursor and activin in Down syndrome pregnancy, *Journal of Medical Screening*, 3: 58-62, 1996.

14. Zheng W, Sung CJ, Hanna I, Depetros G, Lambert-Messerlian G, Steinhoff M and Lauchlan SC. " and \$ subunits of inhibin/activin as sex-cord-stromal differentiation markers. *International Journal Gynecologic Pathology*, 16: 263-271, 1997.
15. Seifer DB, Lambert-Messerlian GM, Hogan JW, Gardiner AC, Blazar AS and Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. *Fertility and Sterility*, 67: 110-114, 1997.
16. Lambert-Messerlian GM, Zheng W, Steinhoff M, Gajewski WH, Seifer DB and Schneyer AL. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. *Gynecologic Oncology*, 65: 512-516, 1997.
17. Welt CK, Martin KA, Taylor AE, Lambert-Messerlian GM, Crowley WF Jr., Smith JA, Schoenfeld DA and Hall JE. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: evidence for FSH control of inhibin B in normal women. *Journal of Clinical Endocrinology and Metabolism*, 82: 2645-2652, 1997.
18. Welt CK, Lambert-Messerlian GM, Zheng W, Sluss P, Crowley WF Jr. and Schneyer AL. The presence of activin, inhibin and follistatin in epithelial ovarian carcinoma. *Journal of Clinical Endocrinology and Metabolism*, 82: 3720-3727, 1997.
19. Lambert-Messerlian G, Taylor A, Leykin L, Isaacson K, Toth T, Chang Y and Schneyer A. Characterization of intrafollicular steroid hormones, inhibin and follistatin in women with and without polycystic ovarian syndrome following gonadotropin hyperstimulation. *Biology of Reproduction*, 57:1211-1216, 1997.
20. Lambert-Messerlian GM, Canick JA, Melegos DN and Diamandis EP. Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. *Clinical Chemistry*, 44:205-208, 1998.
21. Lambert-Messerlian G, Luisi S, Florio P, Mazza V, Canick J and Petraglia F. Second trimester levels of maternal serum total activin A and placental "  $\nabla$  and  $\$EA$  subunit messenger ribonucleic acid in Down syndrome pregnancy. *European Journal of Endocrinology*, 138: 425-429, 1998.
22. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying S, Schneyer AL, Lauchlan SC and Felix JC. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. *Gynecologic Oncology*, 69: 23-31, 1998.
23. Lambert-Messerlian GM, Saller DN Jr, Tumber MB, French CA, Peterson CJ and Canick, JA. Second trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. *Prenatal Diagnosis*, 18: 1061-1067, 1998.
24. Lambert-Messerlian GM, Saller DN Jr, Tumber MB, French CA, Peterson CJ and Canick JA. Second-trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18. *Prenatal Diagnosis*, 19: 476-479, 1999.
25. Silver HM, Lambert-Messerlian GM, Star JA, Hogan J and Canick JA. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic and non-proteinuric gestational hypertensive pregnancy. *American Journal of Obstetrics and Gynecology*, 180:1131-1137, 1999.
- \*26. Lambert-Messerlian GM, Depasquale S, Maybruck WM, Steinhoff MM and Gajewski W. Secretion of activin A in recurrent epithelial ovarian carcinoma. *Gynecologic Oncology*, 74: 93-97, 1999.

27. Phipps MG, Hogan JW, Peipert JF, Lambert-Messerlian GM, Canick JA and Seifer DB. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. *Obstet Gynecol*, 95:227-31, 2000.
28. Lambert-Messerlian GM, Silver H, Petraglia F, Luisi S, Plaino L, Maybruck W, Hogge WA and Canick JA. Second trimester maternal serum levels of inhibin A and human chorionic gonadotropin as markers for prediction of preeclampsia. *Journal of Society for Gynecologic Investigation*, 7:170-174, 2000.
29. Rausch DN, Lambert-Messerlian GM and Canick JA. Participation in maternal serum screening following screen positive results in a previous pregnancy. *Journal of Medical Screening*, 7:3-6, 2000.
30. Fujiwara T, Lambert-Messerlian G, Sidis Y, Leykin L, Isaacson K, Toth T and Schneyer A. Analysis of follicular fluid concentrations and granulosa cell mRNA levels for the inhibin/activin/follistatin system: relationship to oocyte/embryo characteristics. *Fertility and Sterility*, 74:348-355, 2000.
31. Lambert-Messerlian GM, Palomaki GE and Canick JA. Second trimester levels of maternal serum inhibin A in pregnancies affected by fetal neural tube defects. *Prenatal Diagnosis*, 20:680-682, 2000.
32. Dzik A, Lambert-Messerlian G, Izzo VM, Soares JB, Pinotti JA and Seifer DB. Inhibin B response to EFORT is associated with outcome of oocyte retrieval in the subsequent IVF cycle. *Fertility and Sterility*, 74:1114-1117, 2000.
33. Goodwin KM, Sweeney PJ, Lambert-Messerlian GM and Canick JA. High maternal serum levels of inhibin A following the loss of one fetus in a twin pregnancy. *Prenatal Diagnosis*, 20:1015-1017, 2000.
34. Schneyer AL, Fujiwara T, Fox J, Welt CK, Messerlian GM and Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. *Journal of Clinical Endocrinology and Metabolism*, 85: 3319-3330, 2000.
35. Yamamoto H, Lambert-Messerlian GM, Silver HS, Kudo R, Kellner LH and Canick JA. Maternal serum levels of type I and type III procollagen peptides in preeclamptic pregnancy. *Journal of Maternal Fetal Medicine*, 10: 40-43, 2001.
36. Knight GJ, Palomaki GE, Neveux LM, Haddow JE and Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. *Journal of Medical Screening*, 8: 2-7, 2001.
37. Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, Fox J, Taylor A and Schneyer A. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. *Journal of Clinical Endocrinology and Metabolism*, 86:4206-4215, 2001.
38. Malee MP, Verma A, Messerlian G, Tucker R, Vohr, BR. Association between maternal and child leptin levels 9 years after pregnancy complicated by gestational diabetes. *Hormone and Metabolic Research*, 34:212-216, 2002.
39. DePasquale S, Lambert-Messerlian G, Quddus MR, Campbell I, Steinhoff M, Gajewski W, Granai C, Tantravahi U. Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. *International Journal of Gynecological Cancer*, 12:443-447, 2002.

40. Florio P, Ciarmela P, Luisi S, Mercanti V, Lambert-Messerlian G, Severi FM, Petraglia F. Pre-eclampsia with fetal growth restriction: placental and serum activin-A and inhibin-A levels. *Gynecological Endocrinology*, 16:1-8, 2002.
41. Silver HM, Lambert-Messerlian GM, Reis FM, DiBlasio AM, Petraglia F, Canick JA. The mechanisms of increased maternal serum total activin A and inhibin A in preeclampsia. *Journal of Society for Gynecologic Investigation*, 9:308-12, 2002.
42. Lee T, LeShane ES, Messerlian GM, Canick JA, Farina A, Heber WW, Bianchi DW. Down syndrome and cell-free fetal DNA in archived maternal serum. *American Journal of Obstetrics and Gynecology*, 187:1217-21, 2002.
43. Thirunavukarasu PP, Lambert-Messerlian G, Robertson DM, Dawson G, Canick J, Wallace EM. Molecular weight forms of inhibin A, inhibin B and pro-"C in maternal serum, amniotic fluid and placental extracts of normal and Down syndrome pregnancies. *Prenatal Diagnosis*, 22 (12):1086-92, 2002.
44. Wataganara T, LeShane E, Farina A, Messerlian GM, Lee T, Canick JA, Bianchi DW. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. *Human Genetics*, 112:204-8, 2003.
45. Farina A, LeShane E, Lee T, Lambert-Messerlian GM, Canick JA, Bianchi DW. Performance of cell-free fetal DNA as a second trimester maternal serum marker of Down syndrome pregnancy. *Clinical Chemistry*, 49(2): 2003.
46. Seifer DB, Lambert-Messerlian G, Schneyer AL. Ovarian brain-derived neurotrophic factor (BDNF) is present in follicular fluid from normally cycling women. *Fertility Sterility*, 79(2): 451-2, 2003.
47. Plevyak MP, Lambert-Messerlian GM, Farina A, Groome NP, Silver HM. Concentrations of serum total activin A and inhibin A in preterm and term labor patients: a cross sectional study. *Journal of the Society for Gynecologic Investigation*, 1-:231-6, 2003.
48. Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer AL, Canick JA. Inhibins and activins in human fetal abnormalities. *Molecular and Cellular Endocrinology*, 225(1-2):101-8, 2004.
49. Wataganara T, Peter I, Messerlian GM, Borgatta L, Bianchi DW. Inverse correlation between maternal weight and second trimester circulating cell-free fetal DNA levels. *Obstet Gynecol*, 104(3):545-50, 2004.
50. Lambert-Messerlian GM, Canick JA. Placenta growth factor levels in second trimester maternal serum from pregnancies affected with Down syndrome and in prediction of preeclampsia. *Prenatal Diagnosis*, 24: 876-880, 2004.
51. Lambert-Messerlian GM, Pinar H, Rubin L, Canick JA. Second trimester serum markers in pregnancy with a coexisting mole. *Pediatric and Developmental Pathology*, 8(2);230-234, Apr 2005.
52. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Hackshaw AK, Lambert-Messerlian G, D'Alton ME for the FASTER Research Consortium\* First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER): Principal Results of the NICHD Multicenter Down Syndrome Screening Study. *New England Journal of Medicine*, 353(19): 2001-11, Nov 2005.

53. Pan P, Peter I, Lambert-Messerlian GM, Canick JA, Bianchi DW, Johnson KL. Cell-free fetal DNA levels in pregnancies conceived by in vitro fertilization. *Molecular Human Reproduction*, 20(11): 3152-3156, Nov 2005.
54. Welt CK, Taylor AE, Fox J, Messerlian GM, Adams JM, Schneyer AL. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. *Journal of Clinical Endocrinology and Metabolism*, 90: 5582-5587, Oct 2005.
55. Dugoff L, Hobbins JC, Malone FD, Canick JA, Lambert-Messerlian G, Porter TF, Luthy D, Comstock CH, Saade G, Eddleman K, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME for the FASTER Trial Research Consortium. The Quad screen as a predictor of adverse pregnancy outcome. A population based screening study. *Obstetrics and Gynecology*, 106: 260-7, Aug 2005.
56. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JB, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar A. Mullerian inhibitory substance levels at the time of hCG administration in IVF cycles predict both ovarian reserve and embryo quality. *Human Reproduction*, 21(1)159-163, Jan 2006.
57. Lambert-Messerlian G, Eklund E, Malone F, Canick J, Palomaki G, D'Alton M and the FASTER research consortium. Stability of first and second trimester serum markers after shipment. *Prenat Diagn*, 26(1):17-21, Jan, 2006.
58. Lambert-Messerlian GM, Harlow BL. The influence of depression, body mass index and smoking on serum inhibin B levels in late reproductive aged women. *Journal of Clinical Endocrinology and Metabolism*, 91:1496-1500, Mar 2006.
59. Farina A, Lambert-Messerlian GM, Canick JA, Banzola I, Carletti A, Concu M, Tempesta A, Gabrielli S, Morano D, Rizzo N. Total activin A in maternal blood as a marker of preterm delivery in low-risk asymptomatic patients. *Prenatal Diagnosis* 26: 277-81, Mar 2006.
60. Lambert-Messerlian G, Dugoff L, Vidaver J, Canick JA, Malone FD, Ball RH, Comstock CH, Nyberg DA, Saade G, Eddleman K, Klugman S, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME. First and second trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): A FASTER trial study. *Prenatal Diagnosis*, in press, 2006.
61. Palomaki GE, Lambert-Messerlian GM, Canick JC. A summary analysis of Down syndrome markers in the late first trimester. *Advances in Clinical Chemistry*, in press, 2006.

#### **OTHER PUBLICATIONS**

1. Lambert GM. A short review: Exercise and the premenstrual syndrome. *Journal of Applied Sport Science Research* 2(1): 16-19, 1988.
2. Schneyer A, Lambert-Messerlian G, Sluss P, Isaacson K, and Crowley WF Jr. Do alpha inhibin proteins have a role in gonadal physiology? In: *Frontiers in Endocrinology: Inhibin and Inhibin Related Proteins*. Ed. HG Burger et al., Ares Serono Symposium, Serono Symposium Publications, Rome Italy, 1994.
3. Lambert-Messerlian GM, Canick JA and Palomaki GE. Maternal serum total activin A in pregnancies affected with fetal Down syndrome. *Journal of Medical Screening*, 3: 217, 1996 (letter).

4. Lambert-Messerlian G and Canick JA. Endocrine analytes in multiple marker screening. In: Clinics in Perinatology. J Strauss III and W Miller (eds.), W.B. Saunders Co., Philadelphia, PA, 25 (4), 963-981, 1998.
5. Lambert-Messerlian GM. Is inhibin a serum marker for ovarian cancer? European Journal of Endocrinology, 142: 331-333, 2000 (Invited Commentary).
- \*6. Lambert-Messerlian G. Physiology and pathophysiology of inhibin A and activin A in human pregnancy. Current Opinion in Endocrinology and Diabetes, 7: 337-344, 2000 (Review).
7. Canick JA, Messerlian GM, Farina A. General principles of second trimester maternal serum screening for Down syndrome. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2002.
8. Canick JA, Messerlian GM, Farina A. Second trimester maternal serum screening for Down syndrome: Clinical recommendations. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2002.
9. Canick JA, Messerlian GM, Farina A. Pregnancy complications predicted by second trimester maternal serum screening. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2002.
10. Lambert-Messerlian, G. Recent developments in inhibin and activin as ovarian tumour markers. In: Inhibitions (Inhibin and activin research newsletter), 5:2, 2002. (Invited contribution)
11. Messerlian GM, Canick JA. Recent advances in maternal serum screening for Down syndrome. Medicine and Health, Rhode Island, 85:362-5, 2002.
12. Lambert-Messerlian G. The value of inhibin B: predicting success in IVF. Family Building, Resolve: The National Infertility Organization, 2:12, 2002.
13. Lyell DJ, Lambert-Messerlian G, Giudice LC. Prenatal screening, epidemiology, diagnosis and management of preeclampsia. IN: Clinics in Laboratory Medicine, J Canick and G Lambert-Messerlian (eds.), 23(2): 413-442, 2003
14. Florio P, Lambert-Messerlian G\*, Severi FM, Buonocore G, Canick JA, Petraglia F. Fetal neural tube defects: maternal serum and amniotic fluid activin A levels. Prenatal Diagnosis, 24(7):574-5, 2004. (\*co-first author, letter)
15. Lambert-Messerlian G, Halliday J, Williams J, Cain R, Msall M, Palomaki GE, Canick JA. Effect of folic acid supplementation on prevalence of neural tube defects in Rhode Island. Journal of Medical Screening, 11: 106-107, 2004. (letter)
16. Canick JA, Saller DN Jr., Lambert-Messerlian GM. Prenatal screening for Down syndrome: current and future methods. IN: Clinics in Laboratory Medicine, J Canick and G Lambert-Messerlian (eds.), 23(2): 395-412, 2003.
17. Lambert-Messerlian GM, Canick JA. Clinical Application of Inhibin A Measurement: Prenatal Serum Screening for Down Syndrome. IN: Seminars In Reproductive Medicine: Issue on inhibins, GM Lambert-Messerlian and VD Castracane (eds.), 22(3):235-242, 2004.
18. Lambert-Messerlian GM, Keren D, Raphtis CS, Byberg K, Canick JA. Apparently low maternal serum inhibin A levels in second trimester screening. Prenatal Diagnosis, 25(10):967-968, Oct 2005. (Letter)

19. Barrs VA, Canick JA, Lambert-Messerlian GM. Approach to prenatal screening for Down syndrome. In: UpToDate, Barss VA (Ed), UpToDate, Wellesley, MA, 2005.

#### **BOOKS EDITED**

Clinics in Laboratory Medicine, Issue on Prenatal Testing. J Canick and G Lambert-Messerlian (eds), WB Saunders, Philadelphia, PA, 23(2), 2003.

Seminars In Reproductive Medicine, Issue on inhibins, GM Lambert-Messerlian and VD Castracane (eds.), Thieme Publishing, New York, 22(3), 2004.

#### **PUBLICATIONS IN PREPARATION**

Plante BJ, Phipps MG, Blume JD, Lambert-Messerlian G, Shackelton R, Canick J. A multiple marker model to predict pregnancy viability. Submitted, 2006

Lambert-Messerlian GM, Eklund E, Pinar H, Tnatravahi U, Schneyer AL. Activin subunit and receptor expression in normal and cleft human fetal palate tissues. Pediatric and Developmental Pathology, submitted, May 2006.

Urato AC, Peter I, Canick J, Lambert-Messerlian G, Pulkkinen A, Knight G, Jeong Y-J, Johnson K, Bianchi DW. Circulating total cell-free DNA levels are increased in pregnant women who smoke. In preparation, May 2006.

#### **ABSTRACTS**

1. Lambert GM, Erskine MS and Baum MJ. Naloxone augments LH pulse frequency in gonadectomized male and female ferrets before, but not after, estradiol replacement. Society for Neuroscience, St Louis MO, October 1990.

2. Lambert GM, Rubin BS and Baum MJ. Hypothalamic release of LHRH is reduced after mating or gonadectomy in breeding female, but not in male, ferrets. Society for Neuroscience, New Orleans LA, November 1991.

3. Lambert GM, Rubin BS and Baum MJ. Sex difference in the effect of mating on *c-fos* immunoreactivity in LHRH neurons of the ferret. Society for Neuroscience, Anaheim CA, October 1992.

4. Lambert GM and Schneyer AL. Post-translational processing of alpha inhibin in human follicles. 75th Annual Meeting of the Endocrine Society. Las Vegas NV, June 1993.

5. Good TEM, Ireland JLH, Weber PSD, McConnell DS, Padmanabhan V, Schneyer AL, Lambert-Messerlian G, Groome N and Ireland JJ. Isolation and immunological characterization of different inhibin forms. 27th Annual Meeting of the Society for Reproduction, Ann Arbor MI, July 1994.

6. Hall JE, Lambert-Messerlian GM, Christian S, Martin KA, Khoury R, Sluss PM, Groome NP, Crowley WF Jr and Schneyer AL. Dynamics of dimeric inhibin and follicle-stimulating hormone (FSH) secretion during the luteal-follicular transition. 76th Annual Meeting of the Endocrine Society, Anaheim CA, June 1994.

7. Schneyer AL, Lambert-Messerlian GM, Crowley WF Jr, Hall JE, Martin KA, Sluss PM, Taylor AE and Groome NP. Circulating dimeric inhibin levels in men and women using a novel two-site immunoassay. 76th Annual Meeting of the Endocrine Society, Anaheim CA, June 1994 (Oral presentation).

8. Lambert-Messerlian GM, Crowley WF Jr and Schneyer AL. Extragonadal alpha inhibin precursor proteins in human male serum. 76th Annual Meeting of the Endocrine Society, Anaheim CA, June 1994.
9. Canick JA, Lambert-Messerlian GM, Palomaki GE, Schneyer AL, Tumber MB, Knight GJ and Haddow JE. Maternal serum dimeric inhibin is elevated in Down syndrome pregnancy. American Society of Human Genetics. 1994 (Oral presentation).
10. Seifer DB, Canick JA, Frishman GN, Lambert-Messerlian GM and Schneyer AL. Serum total and dimeric inhibin levels are lower in ectopic than in normal spontaneously conceived intrauterine pregnancies. Society for Gynecologic Investigation, Chicago, 1995.
11. Seifer DB, Gardiner AC, Wheeler CA, Lambert-Messerlian GM and Schneyer AL. Differential secretion of inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. Society for Gynecologic Investigation, Chicago, 1995.
12. Schneyer AL, Hall HA, Lambert-Messerlian GM and Crowley WF Jr. Immunological and biochemical differences between hFF and serum derived follistatin (Fs). 77th Annual Meeting of the Endocrine Society, Washington DC, 1995.
13. Canick JA, Kellner LH, Saller DN, Palomaki GE, Tumber MB, Messerlian GM, Walker RP and Osathanondh. A second level evaluation of maternal urinary gonadotropin peptide as a marker for second trimester Down syndrome screening. 3rd Joint Clinical Genetics Meeting, San Antonio TX, 1996.
14. Hall JE, Martin KA, Taylor AE, Khoury R, Sluss P, Lambert-Messerlian G, Schneyer AL and Crowley WF Jr. Reciprocal changes in inhibin B and inhibin A during the normal menstrual cycle. 78th Annual Meeting of the Endocrine Society, San Francisco CA, June 1996.
15. Lambert-Messerlian G, Taylor A, Isaacson K, Leykin L, Toth T, Hall HA and Schneyer A. Intrafollicular inhibin concentrations differ between women with and without polycystic ovarian syndrome. 78th Annual Meeting of the Endocrine Society, San Francisco CA, June 1996.
16. Lambert-Messerlian G, Steinhoff M, Zheng W, Seifer D and Schneyer A. Secretion of dimeric inhibin B and " inhibin subunits in women with epithelial ovarian cancer. 78th Annual Meeting of the Endocrine Society, San Francisco, CA, June 1996.
17. Kellner LH, Canick JA, Palomaki GE, Saller DN, Lambert-Messerlian GM, Nuer M, Osathanondh R and Bombard AT. Urinary markers: a new approach to screening for Down syndrome in the second trimester. American Society for Human Genetics, October 1996.
18. Seifer DB, Lambert-Messerlian GM, Berk C, Gardiner AC, Hogan JW and Blazer AS. Day 3 serum dimeric inhibin B is predictive of outcome in ART. American Society for Reproductive Medicine, Boston, MA, November 1996.
19. Lambert-Messerlian GM and Canick JA. Levels of total activin A in second trimester maternal serum from normal pregnancies and those affected with fetal Down syndrome. International Conference on Inhibin, Activin, Follistatin...Recent Advances and Future Views. Tokushima Japan, November, 1996.
20. Lambert-Messerlian G, Taylor A, Isaacson K, Leykin L, Toth T, Hall HA and Schneyer A. Intrafollicular activin concentrations in women with and without polycystic ovarian syndrome. 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 1997.

21. Welt C, Lambert-Messerlian G and Schneyer A. Serum activin levels in patients with epithelial ovarian cancer. 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 1997.
22. Seifer DB, Phipps M, Lambert-Messerlian G, Palomaki G, Peipert J and Canick JA. Combination of single serum progesterone and inhibin-A differentiates viable from non-viable spontaneously conceived pregnancies in early first trimester. American Society for Reproductive Medicine, Cincinnati, Ohio, October 1997 (Oral presentation).
23. Lambert-Messerlian GM, Tumber MB, Saller DN Jr., French CA, Peterson CJ and Canick JA. Second trimester levels of maternal serum inhibin A in fetal trisomy 18 and in Turner syndrome with and without hydrops. American Society Human Genetics, Baltimore, Maryland, October 1997.
24. Silver H, Messerlian G, Star J, Hogan J and Canick J. Maternal serum inhibin A levels in preeclampsia, nonproteinuric pregnancy-induced hypertension and normotensive pregnancy. Society of Perinatal Obstetricians, Miami Beach, FL, February 1998.
25. Lambert-Messerlian G, Depasquale S, Gajewski W, Maybruck W and Steinhoff M. The patterns of secretion of inhibin pro-alpha C and activin A in recurrent epithelial ovarian carcinoma. New England Association of Gynecologic Oncologists, New Hampshire, June 1998.
26. Blazar AS, Knight G, Messerlian G, Hogan J, Pierce D and Keefe D. Antiphospholipid antibodies impact implantation rate during in vitro fertilization (IVF). American Society for Reproductive Medicine, San Francisco, October, 1998.
27. Lambert-Messerlian GM, Silver H, Petraglia F, Luisi S, Plaino L, Yamamoto H and Canick JA. Second trimester maternal serum levels of inhibin A and human chorionic gonadotropin as markers for prediction of preeclampsia. American Society Human Genetics, Denver, Colorado, October 1998.
28. Rausch DN, Lambert-Messerlian GM and Canick JA. Effects of results of prenatal maternal serum screening on participation in screening in a subsequent pregnancy. American Society Human Genetics, Denver, Colorado, October 1998.
29. Plevyak M, Lambert-Messerlian G, Maybruck W and Silver H. Total serum activin A levels in term and preterm labor. Society for Maternal-Fetal Medicine, San Francisco, California, January 1999.
30. Silver H, Lambert-Messerlian G, Yamamoto H and Canick J. Maternal serum leptin levels in preeclampsia, nonproteinuric gestational hypertension and normotensive pregnancy. Society for Maternal-Fetal Medicine, San Francisco, California, January 1999.
31. Silver HM, Lambert-Messerlian GM and Canick JA. Mechanism of increased maternal serum total activin A and inhibin A in preeclampsia. Society for Gynecologic Investigation, Atlanta, Georgia, March 1999.
32. Plevyak M, Lambert-Messerlian GM, Maybruck W and Silver H. The effect of labor on inhibin A levels. Society for Gynecologic Investigation, Atlanta, Georgia, March 1999.
33. Star J, Silver H, Messerlian G, Tillinghast J and Canick J. Maternal serum inhibin A levels in term diabetic patients with and without hypertensive disease. Society for Gynecologic Investigation, Atlanta, Georgia, March 1999.

34. Dzik A, Izzo VM, Soares JB, Pinotti JA, Messerlian GM and Seifer DB. Prediction of response to controlled ovarian hyperstimulation: A pilot study of delta 24 hours/ inhibin B gonadotropin challenge test. IVF World Congress, Sydney, Australia, May 1999.
35. DePasquale S, Lambert-Messerlian G, Maybruck W, Dukic V, Steinhoff M and Gajewski W. Preoperative evaluation of serum activin A levels in patients with ovarian pathology: benign versus malignant disease. New England Association of Gynecologic Oncologists, Providence, RI, June 1999.
36. Veloudis GM, Seifer DB, Lambert-Messerlian GM, Buyalos. Ovarian volume by magnetic resonance imaging predicts ovarian reserve in premenopausal and postmenopausal women. American Society for Reproductive Medicine, Toronto, Ontario, Canada, September, 1999.
37. Malee MP, Messerlian G, Tucker R and Vohr B. Leptin in the offspring of diabetic gestations: evidence of programming for obesity? Society for Maternal Fetal Medicine, Miami Beach, FL, January 2000.
38. Silver H, Messerlian G and Canick J. Maternal serum activin A and inhibin A levels for prediction of preeclampsia in patients evaluated for "R/O preeclampsia". Society for Maternal-Fetal Medicine, Miami Beach, FL, January 2000.
39. DePasquale S, Lambert-Messerlian G, Steinhoff M, Quddus M, Gajewski W and Tantravahi U. Molecular analysis of activin A and inhibin A subunit gene loci in epithelial ovarian cancer (EOC). SmithKline Beecham National Gynecologic Oncology Fellows Research Meeting, San Diego, CA, February 2000.
40. Lambert-Messerlian GM, Verma A, Heber W and Wheeler C. Peritoneal fluid inhibin A and B levels in women with endometriosis. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000.
41. Levy DP, Navarro JM, Liu H-C, Lambert-Messerlian G, Schattman GL and Rosenwaks Z. Day 3 inhibin-B measurements and immediate IVF outcome following a short GnRH agonist stimulation protocol. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000.
42. Wheeler CA, Heber W and Lambert-Messerlian GM. Inhibin A levels in very early *in vitro* fertilization (IVF) pregnancies are predictive of pregnancy outcome. American Society for Reproductive Medicine, San Diego, October 2000.
43. Knight GJ, Palomaki GE, Neveux LM, Haddow JH, Lambert-Messerlian GM and Canick JA. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down syndrome screening. Inhibins, Activins and Follistatins (Satellite meeting of 11<sup>th</sup> International Congress of Endocrinology), Monash Medical Centre, Melbourne, Australia, October 2000.
44. Simon P, Palomaki G, Williams J, Cain R, Messerlian G, Msall M, Halliday J and Viner-Brown S. Rhode Island birth defects surveillance: a pilot study of open neural tube defects in Rhode Island. National Birth Defects Prevention Network 4<sup>th</sup> Annual Meeting, San Antonio, TX, January 2001.
45. Lambert-Messerlian G, Florio P, Petraglia F, Severi F and Canick J. Activin A levels in pregnancies affected with neural tube defects. 51<sup>st</sup> Annual Meeting of the American Society of Human Genetics, San Diego, CA, October, 2001.
46. Lee T, LeShane ES, Messerlian GM, Canick JA, Carpenter MW, Heber W and Bianchi DW. Fetal Down syndrome is associated with increased cell-free fetal DNA levels in archived maternal serum samples. Society for Maternal Fetal Medicine, New Orleans, LA, January 2002. (Oral presentation)

47. Schneyer A, Fox J, Welt C, Messerlian G, Taylor A. Inhibin A and B biosynthesis is deficient in arrested PCOS follicles relative to size-matched normal follicles. Ovarian Workshop, Baltimore, MD, July 2002.
48. Lambert-Messerlian G, Clark B, Star J, Canick J. Effect of screening covariates on second trimester maternal serum inhibin A levels. Society for Maternal Fetal Medicine, San Francisco, CA, February 2003.
49. Pinar H, Lambert-Messerlian G, Carr S, Canick J. Complete hydatidiform mole coexisting with a live fetus. Northeast Pediatric Pathology Club, Women and Infants Hospital, Providence, RI, April 12, 2003 and Society for Perinatal Pathology, Cincinnati, October 2003.
50. Malone FD, Wald NJ, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Dukes KA, Bianchi DW, Rudnicka A, Hackshaw A, Lambert-Messerlian G, D'Alton ME. First and second trimester evaluation of risk (FASTER) trial: principal results of the NICHD multicenter Down syndrome screening study. Society for Maternal Fetal Medicine, New Orleans, LA, February, 2004
51. Malone FD, Wald NJ, Canick JA, Ball RH, Nyberg DA, Comstock CH, Saade G, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Sullivan L, Rudnicka A, Hackshaw A, Lambert-Messerlian G, D'Alton ME. Use of overall population, center-specific, and sonographer-specific nuchal translucency medians in Down syndrome screening: which is best? (Results from the FASTER trial). Society for Maternal Fetal Medicine, New Orleans, LA, February, 2004
52. Canick JA, Wald NJ, Malone FD, Porter TF, Nyberg DA, Comstock CH, Saade G, Eddleman K, Klugman S, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Sullivan L, Lambert-Messerlian G, Rudnicka A, Hackshaw A, D'Alton ME. Gestational age-based performance of Down syndrome screening markers - results from the FASTER trial. Society for Maternal Fetal Medicine, New Orleans, LA, February, 2004
53. Lambert-Messerlian GM, Palomaki GE, Knight GJ, Neveux LM, Canick JA, Haddow JE. Dimeric Inhibin-A as a Marker for Down Syndrome in the First Trimester. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004.
54. Lambert-Messerlian G, Canick J, Malone F, Porter F, Nyberg D, Comstock C, Saade G, Berkowitz R, Gross S, Dugoff L, Craigo S, Timor I, Carr S, Wolfe H, D'Alton M. First trimester levels of maternal serum hCG and inhibin A in pregnancies affected by fetal trisomy 18: A FASTER Trial study. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004.
55. Jacquelyn Roberson, Suzanne Diment, Angela Miller, Geralyn Lambert-Messerlian, Jacob Canick. Maternal serum integrated screening in clinical practice. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004. (Oral presentation)
56. Messerlian G, Meiri H, Gonen R, Bindra R, Nicoladies K, Canick J. Placental protein 13 (PP-13) as a serum marker for early preeclampsia and IUGR. Placental Association of the Americas (PAA) Conference, Asilomar, CA September 26-29, 2004.
57. Pinar H, Lambert-Messerlian G, Eklund E, Schneyer A. Follistatin related protein (FSRP) expression is a marker of injury in growth impaired term placentas. Annual Perinatal Symposium of the Society for Perinatal Pathology, Little Rock, AK, October 2004.

58. Takoudes T, Weitzen S, Messerlian G, Malee M. Do steroids affect maternal or fetal thrombopoietin in preterm preeclampsia? Society for Maternal Fetal Medicine, Reno, NV, Feb, 2005.
59. Lambert-Messerlian G, Dugoff L, Vidaver J, Canick J, Malone F, D'Alton M on behalf of the FASTER trial consortium. First and second trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): A FASTER trial study. Society for Maternal Fetal Medicine, Reno, NV, February 2005.
60. D'Alton M, Luthy D, Malone F, Canick J, Gravett M, Lambert-Messerlian G, Tomlinson M, Rosenfeld R, Nagalla S. Detection of Down syndrome by proteomic profiling of maternal serum. Society for Maternal Fetal Medicine, Reno, NV, February 2005.
61. Malone F, Lambert-Messerlian G, Canick J, Ball R, Nyberg D, Comstock C, Saade G, Berkowitz R, Gross S, Dugoff L, Craigo S, Timor I, Carr S, Wolfe H, Tripp T, Bianchi D, D'Alton M. First and second trimester evaluation of risk (FASTER) trial: Detection of aneuploidies other than Down syndrome. Society for Maternal Fetal Medicine, Reno, NV, February, 2005.
62. Plante BJ, Phipps MG, Blume JD, Lambert-Messerlian G, Shackelton R, Pollock L. A multiple marker strategy to differentiate viable from non-viable pregnancies. Society for Gynecologic Investigation, Los Angeles, CA, March, 2005.
63. Hartlage SA, Lambert-Messerlian G. Inhibin B as a potential biomarker of symptoms of premenstrual dysphoric disorder (PMDD). 63rd Annual Scientific Conference of the American Psychosomatic Society, Vancouver, British Columbia, Canada, March 2005.
64. Urato A, Peter I, Messerlian G, Canick J, Pulkkinen A, Knight G, Jeong YJ, Craigo S, Bianchi D. Circulating total cell-free DNA levels are increased in pregnant women who smoke. Society for Maternal Fetal Medicine, Miami Beach, FL, February 2006.
65. Cleary-Goldman J, Malone FD, Messerlian G, Sullivan L, Canick J, Ball R, Nyberg D, Gross S, D'Alton M. Subclinical hypothyroidism and pregnancy outcomes: Results from the FASTER trial. Society for Maternal Fetal Medicine, Miami Beach, FL, February 2006.